Humacyte, Inc.
HUMA Healthcare Biotechnology
Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022. In the quarter to June 2026, revenue grew 34.9%, EPS grew 33.3%, free cash flow grew 17.9% and total debt rose 437.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HUMA
Humacyte, Inc. (HUMA) P/E ratio
Humacyte, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 11.0× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | n/m |
| OTLK Outlook Therapeutics, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)